Neurogene Inc (NAS:NGNE)
$ 25.43 -0.37 (-1.43%) Market Cap: 377.76 Mil Enterprise Value: 253.30 Mil PE Ratio: 0 PB Ratio: 2.41 GF Score: 20/100

Neoleukin Therapeutics Inc at Bank of America Healthcare Conference Transcript

May 11, 2022 / 08:20PM GMT
Gregory Allen Harrison
BofA Securities, Research Division - Analyst

Welcome to the afternoon session of Day 2 of the Bank of America Healthcare Conference. My name is Greg Harrison. I'm one of the biotech analysts here at BofA. I also got Mary Kate Davis from the team here with me. And it's my pleasure today to introduce Jonathan Drachman, Chief Executive Officer of Neoleukin Therapeutics. Jonathan, would you like to go through your presentation, and then we can jump into the Q&A after?

Jonathan G. Drachman
Neoleukin Therapeutics, Inc. - CEO, President, Principal Financial Officer & Director

Yes. Thanks, Greg. Thanks, Mary Kate. It's a pleasure to be here. I'm going to go through a couple of the slides from our main deck, which is available on the investor site of our website. And of course, I'll start with our forward-looking statement and refer you to documents, which are in our -- on our website and submitted to the SEC, for a full description of risk factors.

Just as a brief introduction to Neoleukin Therapeutics. The company was founded

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot